Archeonis develops EOlife and EOlife X, advanced pulmonary ventilation systems that utilize artificial intelligence for real-time monitoring and diagnosis of critically ill patients. These solutions enhance patient outcomes by ensuring high-performance ventilation, which is essential for effective cardiopulmonary resuscitation (CPR) and overall respiratory management.
Funding
$9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Critically ill patients require precise pulmonary ventilation, but traditional systems lack real-time monitoring and diagnostic capabilities, potentially leading to suboptimal respiratory management and adverse outcomes. Effective cardiopulmonary resuscitation (CPR) relies heavily on high-performance ventilation, which is often difficult to achieve with conventional methods.
Solution
Archeonis develops EOlife and EOlife X, AI-powered pulmonary ventilation systems designed for real-time monitoring and diagnosis in critically ill patients. These systems enhance patient outcomes by optimizing ventilation performance, a crucial component of effective CPR and overall respiratory support. By integrating artificial intelligence, the solutions provide clinicians with advanced tools for precise ventilation management, ensuring that patients receive the appropriate level of respiratory assistance.
Target Audience
The primary target audience includes hospitals, intensive care units, emergency medical services, and healthcare professionals involved in the respiratory management of critically ill patients.
Features
- AI-driven real-time monitoring of ventilation parameters
- Advanced diagnostic capabilities for identifying respiratory distress
- High-performance ventilation technology optimized for CPR
- EOlife X specifically designed for pediatric ventilation